Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

Table S12 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer

<p>Table S12: List of interactors and antagonists of BRCA1-BRAD1 complex. Fold changes in gene expression are indicated.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Aditi S. Khatpe (15293176) (author)
Andere auteurs:	Rebecca Dirks (15293179) (author), Poornima Bhat-Nakshatri (15293182) (author), Henry Mang (15293185) (author), Katie Batic (15293188) (author), Sarah Swiezy (15293191) (author), Jacob Olson (15293194) (author), Xi Rao (15293197) (author), Yue Wang (15293200) (author), Hiromi Tanaka (15293203) (author), Sheng Liu (15293206) (author), Jun Wan (15090186) (author), Duojiao Chen (15293209) (author), Yunlong Liu (15293212) (author), Fang Fang (14946450) (author), Sandra Althouse (15293215) (author), Emily Hulsey (15293218) (author), Maggie M. Granatir (15293221) (author), Rebekah Addison (15293224) (author), Constance J. Temm (15293227) (author), George Sandusky (15293230) (author), Audrey Lee-Gosselin (15293233) (author), Kenneth Nephew (15293236) (author), Kathy D. Miller (15045080) (author), Harikrishna Nakshatri (14946969) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Carcinogenesis DNA Damage and Repair Small Molecule Agents
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Table S1 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S10 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S11 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S13 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S14 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S15 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S2 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S3 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S4 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Table S9 from TONSL Is an Immortalizing Oncogene and a Therapeutic Target in Breast Cancer
door: Aditi S. Khatpe (15293176)
Gepubliceerd in: (2025)

Supplementary Figure S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S12 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S14 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S15 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S16 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S17 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S18 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S19 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S20 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S21 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S6 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S7 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Figure S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S1 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S10 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S11 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S2 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S3 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S4 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Supplementary Table S5 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
door: Chuandong Geng (17315310)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ile7ioupu7cd54jfpbobnm9hcd